- Details
- (Length of Interview: 17 min) Peter Pinto highlights the paradigm shift to the use of new imaging technology for a more accurate diagnosis of prostate cancer. Targeted MRI/Ultrasound (MR/US) guided biopsy vs TRUS biopsy, full body imaging options such as PET, and Axumin® (fluciclovine F 18) as a staging tool, with mention of metabolic and focal imaging are part of this comprehensive interview. As...
|
- Details
- (Length of video: 9 min) Tom Keane reviews an article entitled, “Comparative Effectiveness of Radical Prostatectomy with Adjuvant Radiotherapy versus Radiotherapy Plus Androgen Deprivation Therapy for Men with Advanced Prostate Cancer”. Men with locally advanced prostate cancer or regionally advanced prostate cancer treated initially with radical prostatectomy plus radiation had a lower risk of pr...
|
- Details
- (Length of Conversation: 18 min) Christopher Sweeney and Alicia Morgans review practice informing data released at the ESMO 2018 meeting from the GETUG 12, ERA 223, and STAMPEDE studies. Biographies: Christopher Sweeney, MBBS, Professor of Medicine, Harvard Medical School, Medical Oncologist, Dana-Farber Cancer Institute Alicia Morgans, MD, MPH Related Content: 12-Year Follow-Up of GETUG-12, A Pha...
|
- Details
- Misha Beltran and Alicia Morgans discuss treatment selection for patients with unique molecular subtypes. They discuss the use of ADT in this patient population as well as chemotherapy. Interestingly, they highlight the shared alteration and learnings from the study of small cell lung cancer. Biographies: Himisha Beltran, MD, Medical Oncologist, Dana Farber Cancer Institute, Harvard Medical School...
|
- Details
- Nick James and Alicia Morgans discuss the quality of life and health economics data from the docetaxel part of the STAMPEDE trial. They also review data presented by Chris Parker on the use of radiotherapy to the primary tumor for men with newly-diagnosed metastatic prostate cancer. Biographies: Professor Nicholas James BSc, MB, BS, FRCP, FRCR, Ph.D., Institute of Cancer and Genomic Sciences NIHR...
|
- Details
- (Length of Discussion: 12 min) Alicia Morgans and Earle Burgess discuss the details of the investigator-initiated trial called ENZADA. They discuss the “why” behind the design of this Phase II trial. Their desire is to understand whether or not triplicate therapy with ADT, plus docetaxel, plus a next gen endocrine agent will further improve outcome over either agent alone in this patient populatio...
|
- Details
- Alicia Morgans and Fred Saad dialogue about the details of this phase 3 trial by the Quebec Cooperative Group of Radiation Oncologists in patients with high-risk localized prostate cancer. The aim of this superiority randomized trial was to compare outcomes of RT combined with either 36 or 18 months of ADT. Biographies: Fred Saad, MD FRCS Professor and Chief of Urologic Oncology, University of Mon...
|
- Details
- Todd Morgan shares the unique program that he and his GU team at the University of Michigan have implemented in an effort to gain a better understanding of the genetics and genomics involved with progression in prostate cancer. Biographies: Todd M. Morgan, M.D. is a urological surgeon specializing in the treatment of genitourinary malignancies and an Associate Professor of Urology and has been at...
|
- Details
- (Length of Discussion: 22 min) Alicia Morgans has a discussion with Dan George uncovering details about the IRONMAN Registry. The objective is to look globally at advanced prostate cancer, both with the metastatic and the castrate-resistant populations, seeking to understand patient outcomes and their experiences through this process. Biographies: Daniel George, MD Alicia Morgans, MD, MPH Read the...
|
- Details
- (Length of Interview: 13 min) Charles Ryan and Gert Attard discuss what is currently being done with regards to serum analysis, plasma analysis, liquid biopsies, circulating tumor cells, in the field of prostate cancer. Biographies: Professor Gerhardt Attard MD Ph.D. FRCP Prof Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. He...
|
